Each week brings new discoveries that change what's possible in medicine. This week, we're covering a breakthrough blood test that could catch one of the deadliest cancers far earlier, and a surprising new discovery about a widely used diabetes drug. We're also looking at new research linking common infections to dementia risk, and an early-stage finding about a protein that may one day help us age better.
Pancreatic cancer is one of the most difficult cancers to treat because it's almost always found too late. Most patients are diagnosed after the cancer has already spread, when surgery is no longer an option.
That's why researchers at the University of Pennsylvania, Mayo Clinic, and the National Institutes of Health have been working on something that could change that picture entirely: a simple blood test.
The team identified two new proteins in the blood called ANPEP and PIGR that show up at elevated levels in people with early-stage pancreatic cancer. When combined with two existing blood markers into a four-marker panel, the test correctly identified pancreatic cancer in more than 91% of cases.
Just as importantly, it detected 87.5% of cancers that were still in the early stages at the point when treatment is most likely to succeed. It can also differentiate pancreatic cancer from conditions like pancreatitis, a key gap in current testing.
The test still needs to be validated in larger studies, especially in people who don't yet have symptoms. But it's a promising step toward making pancreatic cancer screening routine.
Read more: ScienceDaily/ NIH, March 2026
Metformin has been treating type 2 diabetes for over 60 years. It's one of the most prescribed drugs in the world. And until now, doctors believed it worked mainly by reducing sugar production in the liver.
New research from Baylor College of Medicine says that's not the full story.
Scientists found that metformin also acts on the brain, specifically in a region called the ventromedial hypothalamus. It works by suppressing a small protein called Rap1, which then activates neurons that help control blood sugar.
To test this, researchers engineered mice without Rap1 in that brain region. When given low doses of metformin, their blood sugar didn't improve. Other diabetes drugs still worked fine. The drug was also delivered directly into mouse brains at tiny doses, and still lowered blood sugar.
Nothing changes about how or why you should take your medication. But this finding opens the door to more targeted treatments, ones that may work with smaller doses or through entirely new approaches.
It may also help explain something researchers already suspected: that metformin has benefits for brain aging too.
Read more: ScienceDaily/ Baylor College of Medicine, March 2026
We've long known that severe infections seem to raise the risk of dementia. But there's always been a question: is the infection actually causing it? Or are sicker people just more likely to get both?
A large Finnish study took a closer look. It followed more than 60,000 people with dementia and over 300,000 without it, for up to 21 years.
Researchers identified 29 conditions linked to higher dementia risk. These ranged from stroke and Parkinson's to depression and type 2 diabetes. Two of those 29 were infections: urinary tract infections and unspecified bacterial infections.
Here's what stood out. Even after accounting for all the other 27 risk factors, those two infections still independently raised dementia risk. Other conditions explained only 10–14% of that extra risk.
That's a meaningful finding. Researchers believe severe infections may directly speed up cognitive decline, especially in people who are already in the early, silent stages of dementia.
Not every infection is caused by an alarm. But it does highlight how important it is to prevent and treat serious infections quickly, particularly in older adults.
Read more: PLOS Medicine, March 2026
Aging isn't just about disease. For many people, it's the slow loss of strength, bone density, and physical resilience that's hardest to live with.
Researchers call this "inflammaging." It's the chronic, low-grade inflammation that quietly builds up as we age and gradually wears the body down. A new study from the University at Buffalo suggests we may be able to slow down that process.
The key is a protein called TTP. In a healthy body, TTP acts like a brake on inflammation. It targets inflammatory signals in cells and breaks them down. But as we age, TTP levels drop and inflammation rises.
Researchers wanted to see what would happen if TTP didn't decline. So, they engineered older mice to keep the protein stable. The results were striking. Those mice had better grip strength, better endurance, faster movement, and healthier bones. Their immune profiles looked more like younger animals.
This is still early research done in mice. Human trials are a long way off. But it points to a promising new direction, one that targets the inflammation driving aging itself, not just the diseases it causes.
Read more: Aging and Disease, January 2026
This week's research is a reminder that science works on many timescales at once. Some of these discoveries like the pancreatic cancer blood test are closer to changing what's possible in the clinic today.
Others, like the aging protein study, are still years from any human application. But every one of them starts the same way: with researchers asking a question that hasn't been fully answered yet. That's what drives medical progress forward.
Come back next week for another edition of The Weekly Wing. 💚
